MX2022009702A - Moduladores de kv3. - Google Patents

Moduladores de kv3.

Info

Publication number
MX2022009702A
MX2022009702A MX2022009702A MX2022009702A MX2022009702A MX 2022009702 A MX2022009702 A MX 2022009702A MX 2022009702 A MX2022009702 A MX 2022009702A MX 2022009702 A MX2022009702 A MX 2022009702A MX 2022009702 A MX2022009702 A MX 2022009702A
Authority
MX
Mexico
Prior art keywords
modulators
compound
formula
related aspects
aspects
Prior art date
Application number
MX2022009702A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of MX2022009702A publication Critical patent/MX2022009702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)
  • Gyroscopes (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I): (ver Fórmula) y aspectos relacionados.
MX2022009702A 2020-02-06 2020-02-06 Moduladores de kv3. MX2022009702A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (en) 2020-02-06 2020-02-06 Kv3 modulators

Publications (1)

Publication Number Publication Date
MX2022009702A true MX2022009702A (es) 2022-09-07

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009702A MX2022009702A (es) 2020-02-06 2020-02-06 Moduladores de kv3.

Country Status (11)

Country Link
EP (1) EP4100402A1 (es)
JP (1) JP7522203B2 (es)
KR (1) KR20220139923A (es)
CN (1) CN115066424A (es)
AU (1) AU2020427632A1 (es)
BR (1) BR112022013339A2 (es)
CA (1) CA3169057A1 (es)
CL (1) CL2022002081A1 (es)
IL (1) IL295027A (es)
MX (1) MX2022009702A (es)
WO (1) WO2021156584A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2509961T3 (pl) 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
ES2560304T3 (es) * 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
EP2788339B1 (en) 2011-12-06 2016-03-09 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2013175215A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) * 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
EP3853216A4 (en) 2018-09-21 2022-08-10 Bionomics Limited PYRIDINYL SUBSTITUTE COMPOUNDS AND THEIR USES
JP7465868B2 (ja) 2018-10-16 2024-04-11 アウトイフオンイ トヘラペウトイクス リミテッド 新規化合物
WO2020000065A2 (en) 2019-03-25 2020-01-02 Bionomics Limited Substituted-n-heteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
CA3169057A1 (en) 2021-08-12
WO2021156584A1 (en) 2021-08-12
BR112022013339A2 (pt) 2022-09-13
JP2023523501A (ja) 2023-06-06
IL295027A (en) 2022-09-01
AU2020427632A1 (en) 2022-08-18
JP7522203B2 (ja) 2024-07-24
KR20220139923A (ko) 2022-10-17
EP4100402A1 (en) 2022-12-14
CN115066424A (zh) 2022-09-16
CL2022002081A1 (es) 2023-05-26

Similar Documents

Publication Publication Date Title
CL2022002081A1 (es) Moduladores de kv3
PH12020500655A1 (en) Compounds
MX2022011283A (es) Compuestos pirimidoheterocíclicos y aplicación de los mismos.
MX2023003338A (es) Piridonas y pirimidonas tricíclicas.
PH12020551327A1 (en) Compounds
MX2022003494A (es) Azacilos sustituidos como moduladores del miembro 8 de melastatina de potencial receptor transitorio (trmp8).
ZA202101487B (en) Novel compounds
EP4375279A3 (en) Cot modulators and methods of use thereof
CL2021000383S1 (es) Parlante.
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
MX2023008005A (es) Compuestos organicos como activadores del miembro 8 de melastatina de potencial receptor transitorio (trpm8).
MX2023001418A (es) Forma sólida de compuesto.
MX2024001899A (es) Moduladores del canal de potasio.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
WO2020150517A3 (en) Methods of treating tyrosine kinase inhibitor-induced diarrhea
TWD206806S (zh) 錶殼
AU2019226718A8 (en) Compounds that modulates AMPA receptor function
MY195105A (en) Polymeric Amphoteric Surfactant
MX2024000368A (es) Mezclas insecticidas.
TWD229757S (zh) 耳機
WO2023049790A3 (en) Mdm2 degraders and uses thereof
WO2022265574A3 (en) Flux-modulated machine
MX2022005218A (es) Moduladores de miembro 8 de melastatina de potencial receptor transitorio (trpm8).
WO2020003272A8 (en) An improved process for the preparation of venetoclax
WO2023172499A3 (en) Processes for synthesis of withanolides and withaferins and analogs thereof